صورة الغلاف

Biosimilars in Europe

This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.

محفوظ في:

التفاصيل البيبلوغرافية
التنسيق:	Online
اللغة:	الإنجليزية
منشور في:	MDPI - Multidisciplinary Digital Publishing Institute 2023
الموضوعات:	infliximab etanercept TNFα inhibitors biologics biosimilars Germany policies incentives uptake market dynamics biosimilar market biosimilar/supply and distribution biosimilar sustainability Delphi technique pricing reimbursement utilization biosimilar biological information education communication patient Europe adalimumab biosimilarity assessment quality attributes (QAs) potentially critical quality attributes (pCQAs) European public assessment reports (EPARs) clinical governance Spain barriers regulatory review approval clinical queries regulatory science budget impact analysis savings pharmaceutical spending cost containment reference biological competitive market Belgium trastuzumab intravenous subcutaneous HER2-positive breast cancer drug costs healthcare costs cost simulation tender procurement off-patent award criteria switching interchangeability sustainability competition n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries
الوصول للمادة أونلاين:	ONIX_20230202_9783036565750_185
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة: Biosimilars in Europe